Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Multiple myeloma gammopathies

Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. Am J Hematol. 2017;92:435–40.

    Article  Google Scholar 

  2. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–9.

    Article  CAS  Google Scholar 

  3. Lakshman A, Abeykoon JP, Kumar SK, Rajkumar SV, Dingli D, Buadi FK, et al. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. Am J Hematol. 2017;92:1146–55.

    Article  CAS  Google Scholar 

  4. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–31.

    Article  CAS  Google Scholar 

  5. Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130:900–2.

    Article  CAS  Google Scholar 

  6. Khouri J, Bicky T, Reu FJ, Samaras CJ, Liu HD, Karam MA, et al. Daratumumab is safe and highly effective in AL amyloidosis. Blood. 2017;130(Suppl 1):1819–1819.

    Google Scholar 

  7. Kimmich C, Schönland S, Ziehl R, Ho AD, Dittrich T, Müller-Tidow C, et al. Daratumumab monotherapy in thirty-two heavily pre-treated patients with advanced systemic light-chain amyloidosis. Blood. 2017;130(Suppl 1):1837–1837.

    Google Scholar 

  8. Roussel M, Stoppa A-M, Perrot A, Karlin L, Arnulf B, Macro M, et al. A prospective phase II of daratumumab in previously-treated systemic light-chain (AL) amyloidosis. Blood. 2017;130(Suppl 1):508–508.

    Google Scholar 

  9. Sanchorawala V, Sarosiek S, Sloan JM, Brauneis D, Migre ME, Mistark M, et al. Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study. Blood. 2017;130(Suppl 1):507–507.

    Google Scholar 

  10. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26:2317–25.

    Article  CAS  Google Scholar 

  11. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, et al. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia. 2018;32:729–35.

    Article  CAS  Google Scholar 

  12. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121:3420–7.

    Article  CAS  Google Scholar 

  13. Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica. 2014;99:209–21.

    Article  CAS  Google Scholar 

  14. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109:492–6.

    Article  CAS  Google Scholar 

  15. Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood. 2017;129:2120–3.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We acknowledge all the patients, their families and the clinicians who were involved in the patients’ care. This research work has received ASCO 2018 Merit Award.

Author contributions

JPA, SZ and PK designed the study. JPA, SZ and PK collected analyzed and interpreted the data and wrote the first draft of the manuscript. AD, MAG, NL, TK, WG, EM, DD, MQL, SRH, FB, RW, RAK, VR and SK interpreted the data, critically revised the manuscript and all authors approved the final version.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Prashant Kapoor.

Ethics declarations

Conflict of interest

Dr. Gertz has received funding from Amgen, Prothena, Annexon, Appellis, Johnson and Johnson and Celgene. Dr. Dispenzieri has received research funding from Jannsen, Takeda, Celgene, Pfizer, Alnylam, Prothena, and GSK and serves on the advisory board for Takeda and Intellia. Dr. Kumar received research grants for clinical trials from Celgene, Takeda, Janssen, BMS, Sanofi, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech, Amgen. Dr. Leung serves on the advisory board for Takeda and Prothena. Dr. Kapoor is principal investigator on studies for which Mayo Clinic receives funding from Takeda, Sanofi, and Amgen. The remaining authors declare no conflicts of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abeykoon, J.P., Zanwar, S., Dispenzieri, A. et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia 33, 531–536 (2019). https://doi.org/10.1038/s41375-018-0262-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0262-2

This article is cited by

Search

Quick links